LV14963A - Endoteliālās disfunkcijas korektors - Google Patents
Endoteliālās disfunkcijas korektorsInfo
- Publication number
- LV14963A LV14963A LV130088A LV130088A LV14963A LV 14963 A LV14963 A LV 14963A LV 130088 A LV130088 A LV 130088A LV 130088 A LV130088 A LV 130088A LV 14963 A LV14963 A LV 14963A
- Authority
- LV
- Latvia
- Prior art keywords
- corrector
- endothelial dysfunction
- meldonium
- hmg
- thrombosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Izveidota sinerģiska terapeitiska kompozīcija, kas ietver meldonija acetilsalicilskābes aditīvo sāli kā endoteliālās disfunkcijas korektoru un HMG-CoA reduktāzes inhibitoru, trombozes profilaksei un/vai ārstēšanai.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-13-88A LV14963B (lv) | 2013-06-28 | 2013-06-28 | Endoteliālās disfunkcijas korektors |
PCT/LV2014/000006 WO2014209092A1 (en) | 2013-06-28 | 2014-06-27 | Corrector of endothelial dysfunction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-13-88A LV14963B (lv) | 2013-06-28 | 2013-06-28 | Endoteliālās disfunkcijas korektors |
Publications (2)
Publication Number | Publication Date |
---|---|
LV14963A true LV14963A (lv) | 2015-03-20 |
LV14963B LV14963B (lv) | 2015-10-20 |
Family
ID=51352737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-13-88A LV14963B (lv) | 2013-06-28 | 2013-06-28 | Endoteliālās disfunkcijas korektors |
Country Status (2)
Country | Link |
---|---|
LV (1) | LV14963B (lv) |
WO (1) | WO2014209092A1 (lv) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1095695A (en) | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
JP2001500875A (ja) | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
US6596708B1 (en) | 2001-09-07 | 2003-07-22 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
EP1865945A4 (en) | 2005-03-11 | 2008-05-21 | Hong Kong Nitric Oxide Ltd | TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES |
US7598233B2 (en) * | 2005-03-28 | 2009-10-06 | Kowa Co., Ltd. | Method for treating thrombosis |
DE102005025283A1 (de) | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin |
DE102005049293A1 (de) | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
WO2009022821A2 (en) | 2007-08-13 | 2009-02-19 | Hanall Pharmaceutical Company. Ltd | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
RU2364392C1 (ru) | 2008-03-19 | 2009-08-20 | Михаил Владимирович Покровский | Способ коррекции эндотелиальной дисфункции ацетилсалициловой кислотой при l-name индуцированном дефиците оксида азота |
CN102802618B (zh) * | 2009-06-25 | 2014-06-18 | 泰特拉有限公司 | 烟酸和米曲肼的治疗组合 |
KR20120050437A (ko) | 2009-06-25 | 2012-05-18 | 테트라, 시아 | 신규한 아세틸살리실산 염들 |
US20110275649A1 (en) | 2010-05-05 | 2011-11-10 | Palmetto Pharmaceuticals Llc | Combination therapy for the prevention of statin induced diabetes |
KR20120068277A (ko) | 2010-12-17 | 2012-06-27 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제 |
LV14606B (lv) | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
-
2013
- 2013-06-28 LV LVP-13-88A patent/LV14963B/lv unknown
-
2014
- 2014-06-27 WO PCT/LV2014/000006 patent/WO2014209092A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014209092A1 (en) | 2014-12-31 |
LV14963B (lv) | 2015-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
IN2014DN10670A (lv) | ||
MX2015015416A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
NZ732402A (en) | Nitrification inhibitor compositions and methods for preparing the same | |
PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
MX2019005831A (es) | Aptameros para usarse en la inhibicion y/o supresion de la activacion de tlr9. | |
PH12016500497A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
MX348397B (es) | Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico. | |
MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
PH12015502706B1 (en) | Oral formulation for the treatment of cardiovascular diseases | |
IN2014DN08443A (lv) | ||
GB201112145D0 (en) | Means and methods for the treatment of pathological angiogenesis | |
MX2016006240A (es) | Administración de metales pesados para la inhibición de la corrosión de concreto inducida por microbios. | |
TN2015000021A1 (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma | |
LV14963A (lv) | Endoteliālās disfunkcijas korektors | |
MX2017003020A (es) | Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa. | |
MX2015016093A (es) | Trans-clomifeno y sus analogos como agentes que aumentan la densidad mineral osea. |